SkinHealth Systems terminates CRO Ronald Menezes

SkinHealth Systems Inc. reported that its Board of Directors terminated the employment of Chief Revenue Officer Ronald Menezes without cause, effective May 5, 2026.

Rhea-AI Filing Summary

SkinHealth Systems Inc. reported that its Board of Directors terminated the employment of Chief Revenue Officer Ronald Menezes without cause, effective May 5, 2026. The company stated that his departure did not arise from any disagreement over financial reporting, operations, policies, or practices.

SkinHealth plans to negotiate a separation agreement with Menezes setting out any payments or benefits related to his termination. No material terms have been determined yet, and the company expects to file an amendment within four business days after a definitive separation agreement is executed.

Insights

Corporate governance analyst

SkinHealth reports a CRO termination without cause, with separation terms still to be finalized.

SkinHealth Systems Inc. has removed its Chief Revenue Officer, Ronald Menezes, effective May 5, 2026, in a termination classified as without cause. The company explicitly notes there was no disagreement on financial reporting, operations, policies, or practices, which helps limit concern about internal conflicts.

A separation agreement is expected to define any severance payments or continued benefits, but key terms are still under negotiation. An amendment will follow within four business days after the deal is signed, which should clarify the financial and contractual implications of this leadership change.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Chief Revenue Officer, without cause, separation agreement, emerging growth company, +1 more

5 terms

Chief Revenue Officer financial

"terminated Mr. Ronald Menezes' employment as Chief Revenue Officer"

A chief revenue officer is a top executive responsible for overseeing all aspects of generating income for a company, including sales, marketing, and customer relationships. They develop strategies to attract and retain customers, much like a coach guiding a team to score more points. Investors pay attention to this role because it directly influences the company's growth and profitability.

without cause financial

"terminated Mr. Ronald Menezes' employment ... without cause, effective"

separation agreement financial

"The Company intends to enter into a separation agreement with Mr. Menezes"

A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

compensatory arrangements financial

"Compensatory Arrangements of Certain Officers"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change in leadership did SkinHealth Systems (SKIN) disclose?

SkinHealth Systems disclosed that its Board terminated Chief Revenue Officer Ronald Menezes’ employment without cause, effective May 5, 2026. The company also clarified that his departure was not due to any disagreement regarding financial reporting, operations, corporate policies, or business practices.

Was Ronald Menezes’ departure from SkinHealth (SKIN) related to disagreements?

The company stated that Ronald Menezes’ termination as Chief Revenue Officer was not the result of any disagreement with SkinHealth on financial reporting, operations, policies, or practices. This suggests the move is not tied to disclosed disputes over accounting or business conduct matters.

How will SkinHealth Systems (SKIN) handle severance for its former CRO?

SkinHealth intends to enter into a separation agreement with former Chief Revenue Officer Ronald Menezes to document any payments or benefits related to his termination. Negotiations are ongoing, and no material terms have been determined or disclosed as of the filing date.

Will SkinHealth Systems (SKIN) provide more details on the CRO’s separation?

Yes. SkinHealth plans to file an amendment to this report within four business days after it enters into a definitive separation agreement with Ronald Menezes. That amendment is expected to outline the agreed payments or benefits associated with his termination as Chief Revenue Officer.

When did the Chief Revenue Officer’s termination at SkinHealth (SKIN) take effect?

The termination of Ronald Menezes’ employment as Chief Revenue Officer at SkinHealth Systems was effective May 5, 2026. The Board of Directors approved the action on that date, and the company subsequently reported it in a current report signed by its Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:06 PM Learn about SEC filing dates

FALSE0001818093Nasdaq00018180932026-05-052026-05-050001818093us-gaap:CommonStockMember2026-05-052026-05-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2026

SkinHealth Systems Inc.

(Exact name of registrant as specified in its charter)  

Delaware

001-39565

85-1908962

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3600 E. Burnett Street

Long Beach, CA

(Address of principal executive offices)

90815

(Zip Code)

(800) 603-4996

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.0001 per share

SKIN

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐  

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Chief Revenue Officer Departure

On May 5, 2026, the Board of Directors of SkinHealth Systems Inc. (the “Company”) terminated Mr. Ronald Menezes' employment as Chief Revenue Officer of the Company without cause, effective as of May 5, 2026. Mr. Menezes’ termination was not a result of any disagreement with the Company on any matter relating to the Company’s financial reporting, operations, policies or practices.

The Company intends to enter into a separation agreement with Mr. Menezes as soon as practicable in connection with his termination as Chief Revenue Officer of the Company that will document any applicable payments or benefits to be provided to him in respect of such termination. No material terms of the separation agreement have been determined as of the date of this Current Report on Form 8-K (the “Current Report”) and negotiations are ongoing. The Company will file an amendment to this Current Report within four business days after the parties enter into a definitive separation agreement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 6, 2026			SkinHealth Systems Inc.
			By:			/s/ Michael Monahan
			Name:			Michael Monahan
			Title:			Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 15.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 26.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 15.7 KB